Affiliation: Memorial Sloan-Kettering Cancer Center
- Repeated courses of rituximab in chronic ITP: Three different regimensAisha Hasan
Division of Pediatric Hematology, Children s Blood Center, NY Presbyterian Hospital and Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Am J Hematol 84:661-5. 2009..Neither combining rituximab with CVP nor doubling the dose of rituximab increased the response rate...
- Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapiesAisha N Hasan
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Discov Med 8:210-8. 2009....
- Novel strategies for adoptive therapy following HLA disparate transplantsRICHARD J O'REILLY
Marrow Transplantation Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Best Pract Res Clin Haematol 24:381-91. 2011..These approaches may thus provide new, immediately accessible resources for the generation and broad application of immune cell therapies to treat and prevent severe viral diseases post transplant...
- Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemiasEkaterina Doubrovina
Department of Pediatrics, Bone Marrow Transplantation Service and Division of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Blood 120:1633-46. 2012..This series of immunogenic epitopes of WT-1 should prove useful for immunotherapies targeting WT-1(+) malignancies...
- Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplantsRICHARD J O'REILLY
Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
Immunol Res 38:237-50. 2007..New more predictable strategies are under development, which should allow such therapies to be broadly applicable...
- Use of humanized severe combined immunodeficient mice for human vaccine developmentGloria C Koo
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, NY 10021, USA
Expert Rev Vaccines 8:113-20. 2009..Human immune responses could be elicited and assessed in these humanized SCID mice upon vaccination or sensitization with allogeneic tissues. A translational model is proposed to attain preclinical data for testing human vaccines...